4 Key Barriers Holding Biosimilars Back (and how to remove them)

Prescription drug costs increased by nearly 10 percent in 2023 and are expected to rise an additional eight percent in 2025. And pharmacy benefits continue to be the fastest-growing component of health care. 

While an estimated 45% of plan members are using biologics and biosimilars, more affordable, clinically comparable versions of their brand name originals, uptake of these less-expensive alternatives has been slow.

Experts point to several complicating factors influencing the use of biosimilars, including complex formulary structures, higher launch costs, market dynamics, and general public awareness.

RxBenefits Chief Pharmacy Officer Mark Campbell breaks down the challenges with biosimilar adoption that left nearly $6B on the table last year, and the steps needed to turn the trend around, with BenefitsPRO.